Bryce Point Capital LLC Invests $1.78 Million in Sotera Health (NASDAQ:SHC)

Bryce Point Capital LLC acquired a new stake in shares of Sotera Health (NASDAQ:SHC) in the 4th quarter, Holdings Channel reports. The institutional investor acquired 130,424 shares of the company’s stock, valued at approximately $1,784,000. Sotera Health makes up 0.5% of Bryce Point Capital LLC’s holdings, making the stock its 26th largest holding.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Vanguard Group Inc. raised its holdings in shares of Sotera Health by 1.2% in the 4th quarter. Vanguard Group Inc. now owns 14,923,546 shares of the company’s stock valued at $204,154,000 after acquiring an additional 173,341 shares in the last quarter. State Street Corp lifted its position in Sotera Health by 18.5% during the third quarter. State Street Corp now owns 4,126,806 shares of the company’s stock valued at $68,918,000 after purchasing an additional 644,236 shares during the last quarter. Geode Capital Management LLC grew its stake in Sotera Health by 0.9% in the 4th quarter. Geode Capital Management LLC now owns 2,780,445 shares of the company’s stock worth $38,048,000 after buying an additional 25,054 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Sotera Health by 45.1% in the 4th quarter. Bank of New York Mellon Corp now owns 1,630,736 shares of the company’s stock worth $22,308,000 after buying an additional 507,147 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its position in shares of Sotera Health by 18.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,348,917 shares of the company’s stock valued at $22,527,000 after buying an additional 208,914 shares in the last quarter. 91.03% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the stock. Barclays cut their target price on shares of Sotera Health from $17.00 to $16.00 and set an “overweight” rating for the company in a research report on Friday, February 28th. The Goldman Sachs Group began coverage on Sotera Health in a report on Friday, December 6th. They issued a “neutral” rating and a $14.00 price objective for the company. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $16.00.

Sotera Health Price Performance

SHC stock opened at $11.13 on Wednesday. The firm has a market cap of $3.16 billion, a P/E ratio of 44.52 and a beta of 1.92. The firm’s fifty day moving average is $12.77 and its 200 day moving average is $13.91. Sotera Health has a 52 week low of $10.71 and a 52 week high of $17.08. The company has a debt-to-equity ratio of 4.91, a quick ratio of 2.61 and a current ratio of 2.88.

Sotera Health Profile

Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems.